• 1. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Introduction to (S)-3-Methyl-2-butylamine Hydrochloride (CAS No. 31519-53-6)

Chemical compounds play a pivotal role in the pharmaceutical industry, particularly in the development of novel therapeutic agents. One such compound, (S)-3-Methyl-2-butylamine Hydrochloride, with the CAS number 31519-53-6, has garnered significant attention due to its unique structural and functional properties. This compound is a chiral amine derivative, which makes it a valuable intermediate in synthetic chemistry and drug design.

The significance of chiral compounds in pharmaceuticals cannot be overstated. Chirality refers to the property of a molecule that makes it non-superimposable on its mirror image, much like how left and right hands are mirror images but cannot be perfectly aligned. This property is crucial because the biological activity of a drug can be drastically different depending on its chirality. For instance, one enantiomer of a drug may be therapeutically active while the other may be inactive or even harmful. The compound (S)-3-Methyl-2-butylamine Hydrochloride is an example of a single enantiomer, specifically the (S) configuration, which has been extensively studied for its potential applications.

In recent years, there has been a surge in research focused on developing enantioselective synthesis methods to produce pure enantiomers efficiently. This is particularly important for drugs where the presence of even small amounts of the wrong enantiomer can lead to adverse effects. The synthesis of (S)-3-Methyl-2-butylamine Hydrochloride has been optimized using various catalytic systems and asymmetric methodologies. These advancements have not only improved the yield and purity of the compound but have also reduced the environmental impact of its production.

The pharmacological potential of (S)-3-Methyl-2-butylamine Hydrochloride has been explored in several preclinical studies. Its structural features make it a promising candidate for various therapeutic applications. For instance, amine derivatives have been widely used as intermediates in the synthesis of bioactive molecules targeting neurological disorders, cardiovascular diseases, and inflammatory conditions. The (S) configuration specifically may offer enhanced selectivity and reduced side effects compared to its racemic counterpart.

One of the most exciting areas of research involving (S)-3-Methyl-2-butylamine Hydrochloride is its potential in treating neurological disorders. Studies have shown that certain chiral amines can interact with specific receptors in the brain, modulating neurotransmitter activity. The (S) enantiomer of 3-methyl-2-butylamine has been found to exhibit potent effects on dopamine receptors, which are implicated in conditions such as Parkinson's disease and schizophrenia. By targeting these receptors selectively, it may be possible to develop novel therapeutics that offer improved efficacy and safety profiles.

In addition to its neurological applications, (S)-3-Methyl-2-butylamine Hydrochloride has also shown promise in the treatment of cardiovascular diseases. Amines are known to play a role in regulating blood pressure and cholesterol levels. Research indicates that derivatives of this compound can modulate lipid metabolism and improve endothelial function, potentially leading to new treatments for conditions like hypertension and atherosclerosis.

The development of new synthetic routes for (S)-3-Methyl-2-butylamine Hydrochloride has been facilitated by advances in green chemistry principles. These methods focus on reducing waste, minimizing energy consumption, and using environmentally benign solvents and catalysts. For example, biocatalytic approaches using enzymes have been successfully employed to achieve high enantioselectivity in the synthesis of this compound. Such green chemistry practices not only enhance sustainability but also make the production process more cost-effective and scalable.

The analytical characterization of (S)-3-Methyl-2-butylamine Hydrochloride is another critical aspect that has seen significant advancements. Modern analytical techniques such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) provide highly accurate and sensitive methods for determining the purity and enantiomeric excess of the compound. These techniques are essential for ensuring that pharmaceutical-grade materials meet stringent regulatory standards before they can be used in clinical trials or commercial products.

The future prospects for (S)-3-Methyl-2-butylamine Hydrochloride are promising, with ongoing research exploring its potential applications in various therapeutic areas. As our understanding of chiral chemistry continues to evolve, it is likely that new synthetic strategies will emerge, further optimizing the production and application of this compound. Collaborative efforts between academia and industry are essential to translate these laboratory findings into tangible medical breakthroughs that benefit patients worldwide.

In conclusion, (S)-3-Methyl-2-butylamine Hydrochloride (CAS No. 31519-53-6) represents an important class of chiral amine derivatives with significant pharmacological potential. Its unique structural properties make it a valuable intermediate in drug development, particularly for treating neurological and cardiovascular disorders. With continued advancements in synthetic chemistry, green chemistry practices, and analytical techniques, this compound is poised to play a crucial role in future therapeutic innovations.

• 598-74-3(3-Methyl-2-butanamine)
• 34701-33-2((R)-(?)-2-Amino-3-methylbutane)
• 22526-46-1((S)-3-Methyl-2-butanamine)
• 53561-77-6(3,3-dimethylbutan-2-amine;hydrochloride)
• 4083-58-3(2,4-Dimethylpentan-3-amine hydrochloride)
• 63765-93-5(2-Hexanamine,3-propyl-, hydrochloride (1:1))
• 869671-55-6(3-HEXANAMINE, 2-METHYL-, HYDROCHLORIDE, (3R)-)
• 141983-77-9(3-Pentanamine, 2,4-dimethyl-3-(1-methylethyl)-, hydrochloride)
• 758-27-0(3-methylbutan-2-amine hydrochloride (1:1))
• 29772-69-8(2,3-Dimethylbutan-2-amine Hydrochloride)